Bladder cancer pathophysiology

Bladder cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Bladder cancer from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Electrocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Biopsy
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Bladder cancer pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Bladder cancer pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Bladder cancer pathophysiology
CDC on Bladder cancer pathophysiology
Bladder cancer pathophysiology in the news
Blogs on Bladder cancer pathophysiology
Directions to Hospitals Treating Bladder cancer
Risk calculators and risk factors for Bladder cancer pathophysiology

Steven C. Campbell, M.D., Ph.D.

Overview

Genes involved in the pathogenesis of bladder cancer include HRAS, Rb1, PTEN/MMAC1, NAT2, and GSTM1.

Pathogenesis

• Under normal conditions, the bladder, the lower part of the kidneys (the renal pelvises), the ureters, and the proximal urethra are lined with a specialized mucous membrane referred to as transitional epithelium (also called urothelium).
• Most cancers that form in the bladder, the renal pelvises, the ureters, and the proximal urethra are transitional cell carcinomas (also called urothelial carcinomas) that derive from transitional epithelium.
• Urothelial carcinomas may be non-invasive (only in the lining of the bladder) or invasive (growing into other layers of the bladder wall).

Genetics

Genetic mutations:

• HRAS mutation
• Rb1 mutation
• PTEN/MMAC1 mutation
• NAT2 slow acetylator phenotype
• GSTM1 null phenotype

Gross Pathology

• Non-invasive urothelial carcinoma

• On gross pathology, flat lesions or papillary lesions are characteristic findings of non-invasive urothelial carcinoma.

• Invasive urothelial carcinoma